A London biotech startup announced Wednesday that it had found success in treating major depressive disorder with intravenous DMT in a clinical trial. Though follow-up trials will be necessary to ...
In an analysis of studies that examined critically ill patients requiring an increase in blood fluid volume, intravenous use of the fluid hydroxyethyl starch was associated with adverse outcomes. An ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback